UNSPSC 51171939: Esaprazole

This classification denotes an anti-ulcer agent with the molecular formula C12H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38QSU0IB5L, chemically known as 1-piperazineacetamide, n-cyclohexyl- but generally known as esaprazole, which bears US NIH Compound Identifier 68835. European Medicines Agency schedules Esaprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06607MIG.

UNSPSC 51171939 Esaprazole is a Commodity code representing a specific pharmaceutical product, but state and local procurement activity under this code shows minimal alignment with the nominal esaprazole category. Recent opportunities tagged to this code involve broader pharmaceutical and drug testing services procurement rather than esaprazole supply specifically. Issuing bodies include county criminal justice departments, state health and human services commissions, and multistate cooperative purchasing alliances. The scope spans offender drug testing (specimen collection, immunoassay screening, and confirmatory lab analysis), direct-to-manufacturer prescription program exploration, and generic multi-source pharmaceutical and OTC product distribution through authorized wholesalers.

Activity appears concentrated in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 covering approximately 25,031 annual tests across two collection sites in Plano and McKinney; the contract term runs two years commencing September 1, 2026, with three optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without a formal evaluation timeline or budget commitment at that preliminary stage. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026.